International Conference on Antimicrobial Agents and Chemotherapy August 04-06, 2015 Valencia, Spain

Didier Coquoz, PhD in clinical pharmacology, is a 20+ years seasoned pharma R&D executive (VP R&D and CEO). He has been instrumental in the development/regulatory management from drug candidate up to phase III and registration of close to 30 biologics, monoclonal antibodies, peptides, cell-based therapeutics, NCEs, of which 4 reached the market world-wide. He held positions as CEO and VP R&D on both sides of the Atlantic. He currently acts through Copexis S.A. as Chief Development Officer, Chief Regulatory Affairs and Chief Business Development Affairs for different biotechs/mid pharmas in Europe, mostly in immunology.

Monoclonal antibodies, peptides, cell-based therapeutics

Emil Toma has completed his DSc in Microbiology and specialization in infectious diseases in 1971, at the university of Bucharest, Romania. In 1986 he joined the University of Montreal, Canada where he is a full clinical professor in the department of microbiology, immunology and infectious diseases. He has published more than 138 papers in peer-reviewed journals, 5 books and wrote several chapters in 8 other books. He also developed a “boosted-reverse transcriptase inhibitor” (patented in USA, Australia and Canada).

Microbiology and Infectious diseases

Dr. Angel Garcia Martin obtained his Ph.D. in 1999 at the Universidad Autonoma de Madrid (Spain) and the Centro de Biología Molecular Severo Ochoa, focused on transcriptional regulation of T cell activation by cytokines. In 2000 he moved to the National Cancer Institute at Frederick (NIH; USA) for postdoctoral training in oncogene-induced apoptosis. Dr. Garcia Martin returned to Spain in 2005 as investigator for the Renomic Regulation of Rancer group at Centro de Investigación Príncipe Felipe, Valencia. In 2006 he moved to the Bilbao area to work as a senior researcher at Proteomika SL. In March 2007 he joined Inbiomed to start the Regulation of Cell Growth Laboratory. His main research interest is to understand the role of stem cells in cancer through characterization of cancer initiating cells in order to find novel therapeutic and diagnostic/prognostic targets. Later that year he also became Director of Inbiobank, the biorepository of Fundacion Inbiomed dedicated to adult stem cell banking. In July 2013 he co-founded StemTek Therapeutics, a start-up biotech company dedicated to finding new drugs for cancer treatment based on understanding the biology of cancer stem cells. Since September that year he is exclusively dedicated to StemTek Therapeutics serving as CSO and member of the Board. He has published more than 40 papers in international journals and has been serving as an editorial board member for several international groups.

cancer stem cell biology using cell and molecular biology,mechanisms of tumor initiation

Fenglei Wu has completed his PhD at the age of 33 years from Nanjing Medicine University. He is the director of some projects of NSFC, He has published more than 5 papers in reputed journals and has been serving as an editorial board member of repute.

Lung cancer, Oncology

Helene Castel, CR1 Inserm in Laboratory of Neuronal and Neuroendocrine Communication and Differentiation and also a Team Leader in Astrocyte and Vascular Niche in Cell Differentiation and Gliomagenesis

Cancer Therapy, Antibodies

Isabel Portero received her MD at University of Salamanca, Ph.D at University of La Coruña and completed a medical specialization in Internal Medicine & Infectious diseases at “Marques de Valdecilla” University Hospital, Santander, Spain. She has dedicated her career to developing new medicinal products. She has 15 years of experience in the scientific and medical design of experiments and clinical trials for new drugs and biomarkers. She has worked as Medical Director at several Biotech companies and is also professor at the Department of Medicine (Universidad Complutense, Madrid). She leads a scientific group in Advanced Therapies.

Cell Therapy, diseases, medicine